医学
曲妥珠单抗
内科学
耐火材料(行星科学)
肿瘤科
转移性乳腺癌
癌症
肺癌
非小细胞肺癌
抗体-药物偶联物
抗体
乳腺癌
单克隆抗体
免疫学
物理
天体生物学
A549电池
作者
Egbert F. Smit,B.T. Li,Julien Mazières,David Planchard,Kazuhiko Nakagawa,Kōichi Goto,Luis Paz‐Ares,Silvia Novello,J.C.-H. Yang,M-J. Ahn,G. Liu,Kenneth V. Honn,Mehreteab Aregay,R. Shiga,Kapil Saxena,Gerold Meinhardt,Pasi A. Jänne
标识
DOI:10.1016/j.annonc.2021.08.1962
摘要
HER2 mutations are an established molecular target in NSCLC; however, there are no approved therapies for pts with HER2m NSCLC. T-DXd is an antibody-drug conjugate consisting of an anti-HER2 antibody, cleavable linker, and topoisomerase I inhibitor payload. T-DXd is approved globally at a dose of 5.4 mg/kg every 3 weeks (Q3W) in patients with HER2+ metastatic breast cancer and in the US/Japan at 6.4 mg/kg Q3W in patients with HER2+ metastatic gastric cancer. In a ph 2 trial (DESTINY-Lung01; NCT03505710) in pts with relapsed/refractory HER2m NSCLC, who received T-DXd 6.4 mg/kg Q3W, the confirmed objective response rate (ORR) was 61.9% and the median progression-free survival (PFS) was 14 months at the interim analysis (Smit ASCO 2020).
科研通智能强力驱动
Strongly Powered by AbleSci AI